Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging

Autor: Stephen M. Moore, James D. Quirk, Andrew W. Lassiter, Richard Laforest, Gregory D. Ayers, Cristian T. Badea, Andriy Y. Fedorov, Paul E. Kinahan, Matthew Holbrook, Peder E. Z. Larson, Renuka Sriram, Thomas L. Chenevert, Dariya Malyarenko, John Kurhanewicz, A. McGarry Houghton, Brian D. Ross, Stephen Pickup, James C. Gee, Rong Zhou, Seth T. Gammon, Henry Charles Manning, Raheleh Roudi, Heike E. Daldrup-Link, Michael T. Lewis, Daniel L. Rubin, Thomas E. Yankeelov, Kooresh I. Shoghi

Publikováno v: Tomography, Vol 9, Iss 3, Pp 995-1009 (2023)

Preclinical imaging is a critical component in translational research with significant complexities in workflow and site differences in deployment. Importantly, the National Cancer Institute’s (NCI) precision medicine initiative emphasizes the use

Externí odkaz: https://doaj.org/article/c03b45b43e1546d4a22efc4f2e820217

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients

Autor: Chi Yan, Sheau-Chiann Chen, Gregory D. Ayers, Caroline A. Nebhan, Joseph T. Roland, Vivian L. Weiss, Douglas B. Johnson, Ann Richmond

Publikováno v: npj Precision Oncology, Vol 6, Iss 1, Pp 1-6 (2022)

Abstract Acquired resistance to BRAF/MEK-targeted therapy occurs in the majority of melanoma patients that harbor BRAF mutated tumors, leading to relapse or progression and the underlying mechanism is unclear in many cases. Using multiplex immunohist

Externí odkaz: https://doaj.org/article/e4ad515d7bef45609e1d3c63d929983a

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Autor: Chi Yan, Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt, Gregory D. Ayers, Ann Richmond

Publikováno v: Molecular Cancer, Vol 20, Iss 1, Pp 1-21 (2021)

Abstract Background While immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients and has dangerous side effects. The objective here was to identify the feasibility and mecha

Externí odkaz: https://doaj.org/article/82bb453360e248c5bc1c0f112efb95c9

PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis

Autor: Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V. Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona

Publikováno v: Clinical Cancer Research. :OF1-OF10

Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a850abe032c828055182ec36c5ab409
https://doi.org/10.1158/1078-0432.ccr-22-3192

Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial

Autor: Michael O. Harhay, PhD, Alessandro Gasparini, PhD, Allan J. Walkey, MD, MS, Gary E. Weissman, MD, MSHP, Michael J. Crowther, PhD, Sarah J. Ratcliffe, PhD, James A. Russell, MD, on behalf of the Vasopressin and Septic Shock Trial (VASST) Investigators, J. A. Russell, K. R. Walley, C. L. Holmes Boulton, J. T. Granton, P. C. Hebert, D. J. Cooper, S. Mehta, J. Singer, A. C. Gordon, M. M. Storms, S. Jones, G. R. Bernard, A. S. Slutsky, G. A. Wells, A. Gasparini, B. Savage, D. Ayers, R. Woods, K. Wu, M. Maralit, L. Smith, K. Foley, A. Suri, M. Steinberg, B. Howe, P. Galt, A. Higgins, M. E. LeBlanc, A. M. Sutherland, A. Sham, A. McLeod, D. R. Dorscheid, M. Hameed, L. Lazosky, S. Helderweirt, C. Honeyman, T. Terins, D. Chittock, J. Ronco, S. Logie, G. Wood, F. Auld, V. Stedham, M. Mantle, L. Fox, G. D. McCauley, J. D. Rolf, C. Erbacher, G. Martinka, S. Goulding, S. Silverwood, L. Leung, S. Keenan, J. Murray, M. Van Osch, B. Light, M. Dominique, P. Gray, R. Stimpson, S. Rosser, D. Bell, W. Janz, T. McArdle, I. Watpool, A. Matte-Martyn, D. J Cook, E. McDonald, F. Clarke, A. Tkaczyk, N. Zytaruk, T. Stewart, C. Martinez-Motta, R. MacDonald, V. Sivanantham, R. Hodder, J. Foxall, M. Lewis, M. Ward, C. Dos Santos, J. Friedrich, D. Scales, O. Smith, I. DeCampos, A. Richards, H. Michalopoulos, U. Bakshi, W. Sibbald, T. Smith, K. Code, B. Bojilov, C. Dale, M. Keogh, M. Meade, L. Hand, C. Martin, J. Kehoe, V. Binns, M. McGuire, G. Poirier, L. Provost, J. Muscedere, C. Diemer, V. Pellegrino, A. Hilton, S. Morrison, C. Weatherburn, K. Moulden, C. Harry, J. J. Presneill, M. S Robertson, J. F. Cade, B. D. Howe, D. K. Barge, C. A. Boyce, F. Healy, C. Wright, D. Weyandt, J. Barrett, C. Walker, S. Burton, G. Dobb, S. Perryman, J. Chamberlain, L. Thomas, A. Bersten, L. Daly, T. Hunt, D. Wood, B. Patel, J. Larson, M. Rady, G. LeBrun, E. Boyd, R. Rush

Publikováno v: Critical Care Explorations, Vol 2, Iss 4, p e0104 (2020)

Objectives:. Non-mortality septic shock outcomes (e.g., Sequential Organ Failure Assessment score) are important clinical endpoints in pivotal sepsis trials. However, comparisons of observed longitudinal non-mortality outcomes between study groups ca

Externí odkaz: https://doaj.org/article/2056019742ec46f58eab1b0a39ae1800